Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07PMP
|
|||
| Former ID |
DNC010570
|
|||
| Drug Name |
PKI-402
|
|||
| Synonyms |
PKI-402; 1173204-81-3; PKI402; PKI 402; CHEMBL589258; 1-(4-(3-ethyl-7-morpholino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl)phenyl)-3-(4-(4-methylpiperazine-1-carbonyl)phenyl)urea; 1-[4-[3-Ethyl-7-(morpholin-4-yl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-yl]phenyl]-3-[4-[(4-methylpiperazin-1-yl)carbonyl]phenyl]urea; J-504117; ZAXFYGBKZSQBIV-UHFFFAOYSA-N; MLS006010978; SCHEMBL3401810; DTXSID30657809; EX-A040; MolPort-022-902-305; BCP02609; C29H34N10O3; s2739; BDBM50308767; ZINC49745945; ABP000110; AKOS022526182; QC-7256; RL00651
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H34N10O3
|
|||
| Canonical SMILES |
CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1
|
|||
| InChI |
1S/C29H34N10O3/c1-3-39-27-24(34-35-39)26(37-16-18-42-19-17-37)32-25(33-27)20-4-8-22(9-5-20)30-29(41)31-23-10-6-21(7-11-23)28(40)38-14-12-36(2)13-15-38/h4-11H,3,12-19H2,1-2H3,(H2,30,31,41)
|
|||
| InChIKey |
ZAXFYGBKZSQBIV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1173204-81-3
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: di... J Med Chem. 2010 Jan 28;53(2):798-810. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.